Metoprolol Use in Asthma Patients with Cardiovascular Conditions

Guidelines for Use

For patients with mild asthma who require beta-blocker therapy, the American College of Cardiology recommends monitoring respiratory function closely, particularly when initiating therapy. 1
The American College of Cardiology recommends considering starting with a very low dose of metoprolol (e.g., 12.5 mg) to assess tolerability in patients with asthma. 2
Mild wheezing or a history of chronic obstructive pulmonary disease may allow for a trial of a reduced dose of metoprolol (e.g., 12.5 mg) rather than complete avoidance, according to the American College of Cardiology. 2

The American College of Cardiology recommends considering non-dihydropyridine calcium channel blockers (e.g., verapamil or diltiazem) as alternative therapy for conditions like angina or hypertension in asthmatic patients. 1, 2
For patients with non-ST elevation acute coronary syndromes and contraindications to beta blockers, the American College of Cardiology recommends calcium channel blockers as initial therapy. 1

If metoprolol must be used in a patient with a history of asthma, the American College of Cardiology recommends monitoring for wheezing, decreased peak flow, or other signs of bronchospasm. 2

Active asthma is listed as an absolute contraindication for metoprolol according to the American College of Cardiology guidelines 3

In patients with both cardiovascular disease and asthma, the risk-benefit assessment should carefully weigh the cardiovascular benefits against the respiratory risks 4, 5
For patients with COPD without a significant asthmatic component, beta-1 selective blockers like metoprolol may be better tolerated 5
The European Society of Cardiology guidelines note that beta-blockers are only relatively contraindicated in asthma, but not in COPD, with selective beta-1 blockers (like bisoprolol, metoprolol succinate, or nebivolol) being preferred 5

In patients with chronic obstructive pulmonary disease (COPD) who do not have a significant bronchospastic component, beta‑1‑selective blockers such as metoprolol are better tolerated and cause fewer respiratory adverse events compared with non‑selective agents. 6

Metoprolol’s cardio‑selectivity is lost at high daily doses (approximately 200 mg), the dose commonly targeted for heart‑failure therapy; at these concentrations the drug also blocks bronchial beta‑2 receptors, effectively becoming non‑selective and increasing the risk of bronchospasm. 6

The guideline‑recommended target dose for heart‑failure treatment (metoprolol succinate 200 mg per day) is associated with loss of beta‑1 selectivity, making it unsuitable for patients with asthma or severe COPD without careful risk‑benefit assessment. 6

Long‑acting nitrates are recommended as adjunctive therapy for angina when beta‑blockade is contraindicated or risky in patients with asthma, providing anti‑ischemic benefit without respiratory compromise. 6